Vireo Growth (VREOF) Capital Expenditures (2020 - 2026)
Vireo Growth (VREOF) reported Capital Expenditures of $10.8 million for Q1 2026, up 881.82% on a YoY basis from $1.1 million in Q1 2025, and up 9.51% sequentially from $9.9 million in Q4 2025.
Vireo Growth (VREOF) Capital Expenditures (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Capital Expenditures data on file, last reported at $10.8 million in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 881.82% year-over-year to $10.8 million; the trailing twelve-month figure through Mar 2026 stood at $38.0 million (up 219.65% YoY), and the FY2025 full-year result was $28.3 million, up 142.19% from the prior year.
- Capital Expenditures improved to $10.8 million in Q1 2026, from $9.9 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $13.7 million in Q3 2025 to a low of $152079.0 in Q3 2023.
- A 5-year average of $3.6 million and a median of $2.3 million in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures slumped 90.9% in 2023 and soared 3112.91% in 2024, its largest moves.
- Tracing VREOF's Capital Expenditures over 5 years: stood at $623076.0 in 2022, then jumped by 274.33% to $2.3 million in 2023, then advanced by 16.62% to $2.7 million in 2024, then surged by 262.57% to $9.9 million in 2025, then climbed by 9.51% to $10.8 million in 2026.
- Business Quant data shows VREOF's Capital Expenditures at $10.8 million in Q1 2026, $9.9 million in Q4 2025, and $13.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 10.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.80 Mn |
| Mar 31, 2026 | 10.80 Mn |
| Dec 31, 2025 | 9.86 Mn |
| Dec 31, 2025 | 9.86 Mn |
| Sep 30, 2025 | 13.66 Mn |
| Sep 30, 2025 | 13.66 Mn |
| Jun 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 3.70 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | 899,264.00 |
| Mar 31, 2024 | 899,264.00 |
| Dec 31, 2023 | 2.33 Mn |
| Dec 31, 2023 | 2.33 Mn |